Tim Hunter, VP of Reimbursement and Government Affairs, had been speaking to the medical director BlueCross BlueShield (BCBS) of South Carolina (SC) for some time, trying to get Neox® 100 and Neox® 1K covered. Tim found out that the medical director was an ophthalmologist and appealed to his background by explaining the platform technology behind Amniox (the company name at the time of this conversation). Coincidentally, the medical director mentioned the works of Dr. Tseng and how our product was similar to his technology and even told Tim to reach out to him.
Joanne Long, Value Access & Reimbursement Manager, had the idea to leverage the innovation of BioTissue and the rich history of the more than 36 years of NIH grants and over 360 peer-reviewed studies in a cover letter to the medical director of BCBS of SC.
In the cover letter, Joanne used sales training messaging and mentioned how this is the same platform technology used in Prokera, which is covered now for 12 conditions by BCBS of SC, and stated that it works in the wounds just like it does in the eye. The BioTissue name brought legitimacy to our wound product.
The medical director granted Neox 100 and Neox 1K coverage under BCBS of SC for Treatment of Non-healing Diabetic Lower Extremity Ulcers. Out of 100 similar products to Neox 100 and Neox 1K, BioTissue Surgical has two of the eight amniotic products covered by BCBS of SC. As a company, coverage of Neox 100 and Neox 1K is a monumental step toward getting approval from BCBS across the country and VAC approval in hospitals for these products.
“If there is one takeaway to this story, it is that the name change and consolidation of companies to BioTissue make it easier to buy into our products because of our history,” said Tim.
One small step for Tim and Joanne, one giant leap for BioTissue Surgical.